ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for cancer patients, with an initial focus on solid tumors [Overview]. The company's core business model revolves around in-licensing innovative therapeutic candidates, primarily from China, and advancing them through clinical development and potential commercialization globally, excluding Greater China [Overview, Our Team and Approach]. Revenue generation is currently absent, with the company incurring significant operating losses since its inception [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements].

The company's lead product candidate is firmonertinib, an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor (TKI) being developed for non-small cell lung cancer (NSCLC) patients with a broader range of EGFR mutations (EGFRm) than currently served by approved TKIs [Overview]. Firmonertinib is currently approved and commercially distributed by Shanghai Allist Pharmaceuticals, Co. Ltd (Allist) in China as a first-line therapy for classical EGFRm NSCLC [Overview]. ArriVent licensed the global development and commercialization rights for firmonertinib, excluding Greater China, from Allist in 2021 [Overview]. Firmonertinib is being evaluated in pivotal Phase 3 clinical trials for first-line locally advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations (FURVENT trial) and P-loop and-alpha-c-helix compressing (PACC) mutations (ALPACCA trial) [Overview]. The company received Breakthrough Therapy Designation (BTD) for firmonertinib for first-line EGFRm NSCLC with exon 20 insertion from the U.S. Food and Drug Administration (FDA) in October 2023 [Overview], and Orphan Drug Designation for treatment of NSCLC with EGFRm or HER2/HER4 mutations in February 2024 [Overview].

ArriVent is also advancing a pipeline of novel therapeutics, including next-generation antibody drug conjugates (ADCs) [Overview]. This includes ARR-217 (MRG007), a CDH17-targeting ADC for gastrointestinal cancers, which is in Phase 1 clinical development following an exclusive license agreement with Lepu Biopharma Co. Ltd. (Lepu Biopharma) in January 2025 [Overview, Our Antibody Drug Conjugate Collaborations]. Additionally, the company has a research collaboration with Aarvik Therapeutics, Inc. (Aarvik) to discover next-generation ADCs, having identified a preclinical candidate ARR-002 and initiated IND-enabling activities [Overview, Our Antibody Drug Conjugate Collaborations]. A collaboration agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (Alphamab) was also entered into in 2024 to discover, develop, and commercialize novel ADCs for cancer treatment globally, excluding Greater China [Overview, Our Antibody Drug Conjugate Collaborations].

For the fiscal year ended December 31, 2025, ArriVent reported net losses of $166.3 million ¹, compared to $80.5 million ² for the year ended December 31, 2024 [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements]. As of December 31, 2025, the company had an accumulated deficit of $404.6 million ³ [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements]. The company has not generated any revenue since its inception [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements]. Research and development expenses related to the InnoCare Collaboration Clinical Trial amounted to approximately $0.9 million ⁴ as of December 31, 2025 [Licenses, Partnerships and Collaborations — InnoCare Clinical Collaboration Agreement].

In terms of year-over-year comparisons, the net loss significantly increased from $80.5 million ² in 2024 to $166.3 million ¹ in 2025, reflecting increased investment in development activities. The company's financial position is characterized by substantial operating losses and an accumulated deficit, indicating a pre-revenue stage of development.

Significant operational developments during the period include the first patient dosed in the ALPACCA Phase 3 clinical trial in December 2025 [ALPACCA — Our Ongoing Phase 3 Clinical Trial in First-Line Non-Squamous Locally Advanced or Metastatic EGFRm NSCLC Patients with PACC Mutations]. The final data from the FURTHER trial of firmonertinib in first-line patients with locally advanced or metastatic EGFRm NSCLC with PACC mutations was announced in September 2025, showing 16.0 months ⁵ median progression-free survival (mPFS) with firmonertinib 240 mg ⁶ and a confirmed overall response rate (cORR) of 68.2% ⁷ (n=15 out of 22 ⁸ 1L patients at 240mg) [FURTHER — Our Ongoing Phase 1b Clinical Trial in NSCLC Patients with EGFR Activating Mutations including PACC Mutations]. The median duration of response (DOR) was 14.6 months ⁹ [FURTHER — Our Ongoing Phase 1b Clinical Trial in NSCLC Patients with EGFR Activating Mutations including PACC Mutations]. Additionally, 47% ¹⁰ (n=8/17 ¹¹) of patients with brain metastases at baseline experienced a confirmed response [FURTHER — Our Ongoing Phase 1b Clinical Trial in NSCLC Patients with EGFR Activating Mutations including PACC Mutations]. The company also entered into the Exclusive License Agreement with Lepu Biopharma in January 2025 for ARR-217 [Licenses, Partnerships and Collaborations — Lepu Biopharma Agreement].

ArriVent BioPharma anticipates topline data from its pivotal Phase 3 FURVENT clinical trial for firmonertinib in first-line non-squamous locally advanced or metastatic EGFRm NSCLC patients with exon 20 insertion mutations in mid-2026 [FURVENT — Our Ongoing Phase 3 Clinical Trial in First-Line Non-Squamous Locally Advanced or Metastatic EGFRm NSCLC Patients with Exon 20 Insertion Mutations]. The company has completed enrollment of 398 patients ¹² in this global trial, which is designed to assess the safety and efficacy of firmonertinib at 160 mg ¹³ or 240 mg ¹⁴ once-daily compared to platinum-based chemotherapy with pemetrexed [FURVENT — Our Ongoing Phase 3 Clinical Trial in First-Line Non-Squamous Locally Advanced or Metastatic EGFRm NSCLC Patients with Exon 20 Insertion Mutations].

A major growth area for ArriVent is the continued development of firmonertinib for a broad array of EGFRm NSCLC indications [Our Strategy]. This includes advancing firmonertinib through the pivotal Phase 3 ALPACCA clinical trial for EGFRm NSCLC patients with PACC mutations, with the first patient dosed in December 2025 [ALPACCA — Our Ongoing Phase 3 Clinical Trial in First-Line Non-Squamous Locally Advanced or Metastatic EGFRm NSCLC Patients with PACC Mutations]. The ALPACCA trial plans to enroll 480 patients ¹⁵ and will assess firmonertinib 240 mg ¹⁶ once-daily against investigator's choice of osimertinib or afatinib, with co-primary endpoints of ORR and PFS [ALPACCA — Our Ongoing Phase 3 Clinical Trial in First-Line Non-Squamous Locally Advanced or Metastatic EGFRm NSCLC Patients with PACC Mutations]. PACC mutations account for over 12% ¹⁷ of EGFRm NSCLC patients, representing a significant unmet medical need where current guidelines for TKIs are not established [Our Strategy]. The company believes firmonertinib's observed activity in preclinical studies and clinical trials, including the FURTHER trial's 16.0 months ⁵ mPFS and 68.2% ⁷ cORR in first-line PACC patients at 240 mg ⁶, positions it as a potential leading treatment option [Our Strategy].

Another growth vector involves advancing novel therapeutic product candidates, leveraging innovative platforms and technologies, starting with ADCs [Our Strategy]. This includes the development of ARR-217, a CDH17-targeting ADC for gastrointestinal cancers, which is currently enrolling patients in a Phase 1 clinical study [Our Strategy]. The company also aims to discover and develop differentiated next-generation ADCs for solid tumors through collaborations with Aarvik and Alphamab, having identified preclinical candidate ARR-002 and initiated IND-enabling activities [Our Strategy]. The strategy also includes evaluating firmonertinib in the adjuvant setting for NSCLC patients with uncommon EGFRm, with an intent to participate in or conduct a parallel global Phase 3 clinical trial in 2026, depending on the results of the FURVENT study [Planned Adjuvant Study in NSCLC Patients with Uncommon EGFRm, including Exon 20 Insertion and PACC Mutations].

Operationally, ArriVent plans to continue engaging in business development activities to source additional innovative therapeutics in underserved oncology areas, evaluating research collaborations, partnerships, and licensing arrangements to expand its development pipeline [Overview]. The company's strategy emphasizes in-licensing high-quality development candidates, particularly from China, for global development and commercialization [Our Team and Approach].

Regarding capital allocation, ArriVent expects its expenses to substantially increase as it conducts ongoing and planned clinical trials, seeks regulatory approvals, and potentially commercializes product candidates [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements]. The company is obligated to make development and regulatory milestone payments to Allist up to an aggregate of $110.0 million ¹⁸, of which $5.0 million ¹⁹ has been paid, and commercial milestone payments up to $655.0 million ²⁰ [Licenses, Partnerships and Collaborations — Allist Agreements]. Tiered royalties ranging from high single digits to low mid-teens ²¹ percentages on net sales of Licensed Products are also due to Allist [Licenses, Partnerships and Collaborations — Allist Agreements]. For Lepu Biopharma, the company is entitled to a one-time upfront payment and near-term milestone payments totaling $47.0 million ²² in cash and is eligible to receive up to $1.16 billion ²³ in development, regulatory, and sales milestones, plus tiered royalties in high single-digit to low-teen percentages ²⁴ on net sales in the ArriVent Territory [Licenses, Partnerships and Collaborations — Lepu Biopharma Agreement]. Aarvik is eligible for combined regulatory and sales milestone payments not exceeding $98.0 million ²⁵ per product and mid-single digit ²⁶ tiered royalties on net sales, plus less than 1% ²⁷ to Aarvik's upstream licensor [Licenses, Partnerships and Collaborations — Aarvik Research Collaboration Agreement]. Alphamab is entitled to an upfront payment and potential development and sales milestone payments up to an aggregate of $615.5 million ²⁸, and low- to mid-single digit percent ²⁹ royalties on net sales outside Greater China [Licenses, Partnerships and Collaborations — Alphamab Collaboration]. The company believes its existing cash and cash equivalents, including proceeds from its initial public offering, will fund operations through at least twelve months ³⁰ from the financial statements' issuance date [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements]. ArriVent filed an automatic universal shelf registration on Form S-3 in February 2025, registering for sale up to $250 million ³¹ of common stock under an at-the-market program sales agreement [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements].

The company explicitly flags structural headwinds related to its supply chain, particularly its reliance on Chinese third-party manufacturers for firmonertinib, ARR-217, and ARR-002 [Manufacturing, Risks Related to Our Reliance on Third Parties]. The National Defense Authorization Act for Fiscal Year 2026, including the BIOSECURE Act, prohibits federal contracting with certain biotechnology companies of concern, which may limit ArriVent's ability to obtain federal grants or sell products to the federal government if its manufacturers are impacted [Manufacturing]. The company is taking measures to strengthen its supply chain, including identifying alternative potential manufacturers to ensure a sufficient stockpile of drug substance and drug product in the United States [Manufacturing]. Geopolitical risks, including trade disputes between the United States and China, are also identified as potential adverse impacts on financial condition and results of operations [Risks Related to Our Business Operations and Industry].

ArriVent BioPharma faces material risks across several domains. Operationally, the company has incurred significant operating losses, with net losses of $166.3 million ¹ in 2025 and an accumulated deficit of $404.6 million ³, and expects to incur substantial losses for the foreseeable future, potentially never achieving profitability [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements]. The company is heavily dependent on the success of firmonertinib, and any delays in clinical development, regulatory approval, or commercialization would materially harm the business [Risks Related to the Development and Regulatory Approval of Our Product Candidates]. Clinical trials are lengthy, expensive, and uncertain, with high failure rates, and interim data may not be predictive of final results [Risks Related to the Development and Regulatory Approval of Our Product Candidates]. Patient enrollment and retention in clinical trials are challenging, especially for rare indications, and difficulties could lead to increased costs or program abandonment [Risks Related to the Development and Regulatory Approval of Our Product Candidates]. Adverse side effects or safety risks associated with product candidates could delay or preclude regulatory approval, limit commercial profiles, or lead to significant negative consequences, as evidenced by TRSAEs observed in firmonertinib trials, including a 4.6% ³² discontinuation rate due to TRAEs across FURLONG, FAVOUR, Furmo-003, and FURTHER trials [Risks Related to the Development and Regulatory Approval of Our Product Candidates]. The company's reliance on Chinese third-party manufacturers for firmonertinib, ARR-217, and ARR-002 for clinical and potential commercial supply exposes it to supply disruptions, increased costs, and geopolitical risks, including the impact of the BIOSECURE Act [Risks Related to Our Reliance on Third Parties]. Geopolitical developments, such as the Russia-Ukraine and Middle East conflicts, and global supply chain disruptions, increase economic uncertainty and may affect financing [Risks Related to Our Business Operations and Industry]. Regulatory risks include the lengthy and unpredictable FDA approval process, the potential for foreign clinical trial data (especially from China) not to be accepted by the FDA, and the possibility that Breakthrough Therapy or Fast Track designations may not accelerate approval or could be withdrawn [Risks Related to the Development and Regulatory Approval of Our Product Candidates]. Post-approval, the company would be subject to ongoing regulatory obligations and potential market withdrawal if compliance is not maintained or problems arise [Risks Related to Commercialization of Firmonertinib, Our Other Product Candidates, and any Future Product Candidates]. Competitive risks are significant, with numerous larger, better-funded pharmaceutical companies developing competing therapies, potentially leading to superior, safer, or less expensive alternatives [Risks Related to Commercialization of Firmonertinib, Our Other Product Candidates, and any Future Product Candidates]. Intellectual property protection is vital, and the inability to obtain or maintain sufficient patent protection for firmonertinib or other candidates, or challenges to existing patents, could adversely affect commercialization [Risks Related to Our Intellectual Property]. Furthermore, the company is subject to complex and evolving U.S. and foreign healthcare laws and regulations, including data privacy laws like GDPR, UK GDPR, and China's Cybersecurity Law, Data Security Law, and PIPL, with potential for significant fines (e.g., up to RMB 50 million ³³ or 5% ³⁴ of prior year's total annual revenue under PIPL [Risks Related to Our Business Operations and Industry]) and operational disruptions for non-compliance or cybersecurity incidents [Risks Related to Our Business Operations and Industry].

Management's overall tone emphasizes a strategic focus on leveraging deep drug development experience and a global network to identify, develop, and commercialize differentiated oncology medicines, with an initial focus on solid tumors. They highlight the potential of their lead product candidate, firmonertinib, in addressing unmet medical needs in NSCLC patients with uncommon EGFR mutations, citing preliminary clinical evidence from trials like FAVOUR and FURTHER. Management's strategic priorities include maximizing the potential of firmonertinib by advancing it through pivotal Phase 3 trials (FURVENT and ALPACCA) for exon 20 insertion and PACC mutations, respectively, and exploring its use in the adjuvant setting and in combination strategies to overcome resistance [Our Strategy]. A second key priority is to advance novel therapeutic product candidates, particularly next-generation ADCs, through existing collaborations with Aarvik, Alphamab, and Lepu Biopharma, and to continue to broaden the pipeline through expanded business development initiatives, focusing on in-licensing innovative therapies globally, particularly from China [Our Strategy]. Management explicitly states their belief that existing cash and cash equivalents, including proceeds from the recently completed initial public offering, will enable them to fund operations through at least twelve months ³⁰ from the issuance date of the financial statements [Risks Related to Our Limited Operating History, Financial Position and Capital Requirements]. They also expect topline data from the FURVENT clinical trial in mid-2026 [FURVENT — Our Ongoing Phase 3 Clinical Trial in First-Line Non-Squamous Locally Advanced or Metastatic EGFRm NSCLC Patients with Exon 20 Insertion Mutations].